Skip to main content

Dianthus Therapeutics, Inc.

corporate_fare Company Profile

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed DNTH - Latest Insights

DNTH
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
DNTH
Mar 13, 2026, 8:40 PM EDT
Source: Wiseek News
Importance Score:
8
DNTH
Mar 12, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
DNTH
Mar 11, 2026, 5:28 PM EDT
Filing Type: 424B5
Importance Score:
8
DNTH
Mar 10, 2026, 10:56 PM EDT
Source: Reuters
Importance Score:
8
DNTH
Mar 10, 2026, 9:54 PM EDT
Filing Type: S-3MEF
Importance Score:
8
DNTH
Mar 09, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
9
DNTH
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
DNTH
Mar 09, 2026, 7:21 AM EDT
Filing Type: 10-K
Importance Score:
9
DNTH
Mar 09, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
9
DNTH
Jan 28, 2026, 4:25 PM EST
Filing Type: S-3
Importance Score:
7
DNTH
Jan 12, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
8